Quick Answer
Tarsus Pharmaceuticals, Inc. reported Stockholders Equity of $343.43 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $343.43M | +53.0% |
| 2024 | $224.53M | +14.0% |
| 2023 | $196.99M | +2.1% |
| 2022 | $192.90M | +15.7% |
| 2021 | $166.73M | +0.5% |
| 2020 | $165.98M | +2864.0% |
| 2019 | -$6.00M | -343.5% |
| 2018 | -$1.35M | -2977.3% |
| 2017 | -$44.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $335.08M | +41.1% | +0.7% |
| June 30, 2025 | $332.61M | +31.9% | -2.9% |
| March 31, 2025 | $342.46M | +24.4% | +52.5% |
| December 31, 2024 | $224.53M | +14.0% | -5.5% |
| September 30, 2024 | $237.48M | +11.1% | -5.9% |
| June 30, 2024 | $252.25M | +70.7% | -8.3% |
| March 31, 2024 | $275.21M | +58.7% | +39.7% |
| December 31, 2023 | $196.99M | +2.1% | -7.8% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +53.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Tarsus Pharmaceuticals, Inc.’s stockholders equity has grown by 780613.6% (from -$44.0 thousand to $343.43 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: